Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dry powder vancomycin compositions and associated methods

A vancomycin and composition technology, applied in the field of dry powder, can solve the problems of patient burden, inappropriate dose, no vancomycin dry powder, etc.

Inactive Publication Date: 2014-04-09
SAVARA
View PDF13 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, off-label use of approved drugs may put patients at risk because their safety and efficacy have not been studied and / or may provide inappropriate dosages
Additionally, drug delivery by nebulization can take up to 20 minutes, which is a significant burden on the patient
Currently, there is no known commercially available dry powder inhalation form of vancomycin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry powder vancomycin compositions and associated methods
  • Dry powder vancomycin compositions and associated methods
  • Dry powder vancomycin compositions and associated methods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Dry powder vancomycin compositions were manufactured in high yields (75-95%) and in two different batch sizes (1 g and 20 g) without loss of purity using a Buchi laboratory scale spray dryer. These powders showed very high delivery efficiency and lot-to-lot consistency.

[0055] The full aerodynamic particle size distribution of the 20g batch is shown in figure 1 , the figure shows that the vast majority of the particle size distribution is smaller than 5 μm and that a large proportion (about 59%) is within the ultrafine particle fraction (3 μm) predicted for deep lung delivery.

[0056] Preliminary studies have shown that the delivered dose content uniformity of vancomycin powder readily meets the technical requirements of FDA's draft guidance on aerosol dose uniformity. In the last 10 years, this has become one of the biggest challenges facing the pulmonary drug delivery industry. The technical requirements state that no more than one out of 10 times should be outs...

Embodiment 2

[0074] As mentioned above, in some embodiments, the dry powder vancomycin composition of the present invention can be prepared by spray drying. This method has proven to be very efficient and shows excellent batch-to-batch consistency.

[0075] Table 3 below shows primary particle size and moisture content data for batch sizes ranging from 25 g to 100 g, which were prepared by spray drying. x 10 、X 50 and x 90 are the mass diameters of the particles below which 10%, 50% and 90% of the distribution falls, respectively. ND = not determined.

[0076] Also, for lot number G-11-26-1, Figure 6 The complete aerodynamic particle size distribution is shown in and shows that the vast majority of the particle size distribution is smaller than 5 μm (85%) and a large fraction (about 70%) is in the ultrafine particle fraction (<3 μm) expected for deep lung delivery. )Inside.

[0077] table 3

[0078]

[0079]

[0080] Figure 7 Shows that the delivered dose content uniformit...

Embodiment 3

[0086] Vancomycin-leucine formulations contain carbohydrate bulking agents. The formulation was subjected to a chemical stability study at 50°C for 4 weeks. Figure 8 It is shown that the addition of a carbohydrate bulking agent (eg, trehalose) can improve the chemical stability of the dry powder vancomycin composition of the present invention.

[0087] Two lots of vancomycin compositions containing 10% leucine were compared. One of the batches contained no process modifications (Lot SA010) and the other was processed under a nitrogen atmosphere and protected from light and moisture (Lot G-11-026-1). Such as Figure 9 As shown in , these modifications significantly delayed the degradation of vancomycin. Indeed, extrapolation of these data indicates that the composition is stable at room temperature for at least 2 years.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Tap densityaaaaaaaaaa
Login to View More

Abstract

Dry powder vancomycin compositions and methods for administering and preparing such compositions. A composition of the present disclosure may be administered to a subject via pulmonary administration in an amount effective to treat and / or prevent a bacterial infection in the subject. Administration of an effective amount of a composition of the present disclosure may be particularly useful in treating a gram-positive bacterial infection in a subject suffering from pneumonia, cystic fibrosis, bronchiectasis, or other chronic lung disease with a bacterial infection of the subject's airway and / or lung.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Patent Application Serial No. 61 / 487,971, filed May 19, 2011, the contents of which are incorporated herein by reference. Background technique [0003] Vancomycin is a glycopeptide antibiotic used in the prevention and treatment of infections caused by Gram-positive bacteria. Vancomycin is the International Nonproprietary Name (INN) corresponding to the compound having the formula: [0004] [0005] It has been suggested that vancomycin acts by inhibiting cell wall synthesis in Gram-positive bacteria. More specifically, vancomycin is thought to prevent the incorporation of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) glycan subunits into the peptidoglycan matrix; the peptidoglycan matrix forms Gram-positive bacteria The main structural component of the cell wall. Binding of vancomycin to the terminal D-alanyl-D-alanine moieties of NAM and NAG-peptides prevents the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/14
CPCA61K38/14A61K31/198A61K9/0075A61K9/1617A61P11/00A61P31/00A61P31/04A61K2300/00A61K9/4808A61K2121/00
Inventor J·洛德J·T·乔希凯宁H·E·斯奈德P·索尼M-C·郭
Owner SAVARA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com